Related Experiment Videos
[Chemotherapy-associated hemolytic uremic syndrome--a case report]
1Dept. of Clinical Cancer Chemotherapy, Tohoku University, Sendai, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|September 1, 1992
Summary
Mitomycin C (MMC) chemotherapy for esophageal and stomach cancer caused a patient to develop microangiopathic hemolytic anemia and thrombocytopenia. The patient died due to microthrombi, with MMC presumed as the cause.
Area of Science:
- Oncology
- Hematology
- Toxicology
Background:
- A 63-year-old male patient received six months of combination chemotherapy for double esophageal and stomach cancer.
- The regimen included adriamycin, cisplatin, mitomycin C (MMC), 5-fluorouracil, and vindesine.
Observation:
- The patient reported lassitude during chemotherapy.
- Laboratory tests revealed microangiopathic hemolytic anemia, thrombocytopenia, and hyperbilirubinemia.
Findings:
- Despite supportive care with prednisolone, dipyridamole, and fresh frozen plasma, the patient's condition rapidly deteriorated.
- Postmortem examination confirmed multiple microthrombi in the liver, kidney, and pancreas.
Implications:
- This case suggests a potential link between mitomycin C and severe thrombotic microangiopathy.
- Awareness of this adverse effect is crucial for managing patients undergoing similar chemotherapy regimens.
- Further investigation into MMC-induced thrombotic microangiopathy is warranted.